翻訳と辞書 |
GlySens ICGM : ウィキペディア英語版 | GlySens ICGM
GlySens, a biomedical technology company, is a privately owned corporation developing a long term internal continuous glucose monitor in order to effectively manage and observe glucose levels in real-time.The GlySens ICGM system is the world's first surgically implanted CGM system to demonstrate an 18-month performance in a preclinical setting. GlySens Incorporated was founded in1998 by David A. Gough and Joseph Lucisano, a UCSD Bioengineering graduate. The ICGM system uses an internal sensor equipped with electro-chemical detectors to measure glucose readings via a chemical reaction between enzymes and oxygen. With an expected release in 2016, the GlySens ICGM will be the first publicly available glucose monitor capable of withstanding 12+ months of continual use. As the global population of diabetics approached 400 million, this device can dramatically improve the quality of diabetic care. ==Technology== The technology that goes into the ICGM device consists of two parts. Primarily is the internal sensor which utilizes chemical reactions to determine blood glucose levels. Additionally is an external receiver used to display glucose readings and patterns in real-time, helping reduce the level of care needed in diabetics.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「GlySens ICGM」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|